Pep IQ
← Pep IQ
Substantial preclinical foundation. Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, TKPRPGP) — the natural tetrapeptide tuftsin (an immunoregulatory fragment from the Fc region of immunoglobulin G heavy chains) extended with a stabilising Pro-Gly-Pro tail to resist peptidase degradation. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences with the V.V. Zakusov Research Institute of Pharmacology under Nikolai Myasoedov. Mechanism: GABAergic modulation, BDNF upregulation in hippocampus (Inozemtseva 2008), monoamine influence on serotonin metabolism, IL-6 modulation and T-helper cytokine balance, enkephalinase inhibition producing sustained endogenous opioid-peptide tone. Selank affects GABAergic gene expression in rat frontal cortex (PMC 4757669). The 300 mcg/kg dose is the most-effective anxiolytic dose in rat models.
Standard community protocol: 200–400 mcg per nostril intranasal, 2–3× daily, 14-day courses (mirroring Russian clinical protocol). SubQ alternative: 250–500 mcg/day. Cerebrospinal fluid penetration is rapid — peak CSF concentration within ~30 minutes of intranasal dosing. Selank does not require traditional loading — some users notice anxiolytic effect within first dose, others over several days. Russian clinical studies found no tolerance development over 14-day courses, but cycling 2–4 weeks on / equal off is the conservative community pattern. Often stacked with Semax (parallel Russian-developed peptide) — Selank for anxiolytic balance, Semax for cognitive enhancement.
Substantial Russian clinical evidence base — limited Western replication. Open-label and controlled clinical trials in Russia have documented anxiolytic efficacy comparable to standard benzodiazepine and SSRI treatments, with one published study comparing Selank's anxiolytic effect to medazepam in generalized anxiety disorder. The largest body of literature sits in Russian-language psychiatric journals. No FDA-registered or EMA-registered Phase 3 trials exist. The Russian trial methodology is generally less rigorous than Western drug-development standards (open-label designs, smaller sample sizes), so Western readers should view the evidence as suggestive rather than definitive.
Approved as a prescription anxiolytic in Russia and Ukraine — used for generalized anxiety disorder, adjustment disorder with anxious mood, and related indications. Not FDA-approved or EMA-approved. Available via compounding pharmacies in some Western markets and via research peptide vendors elsewhere. Generally well-tolerated — no sedation (unlike benzodiazepines), no cognitive impairment, no tolerance over 14-day courses in Russian studies. WADA does not list Selank.
Selank is among the better-evidenced nootropic-class peptides on the platform — Russian regulatory approval reflects decades of clinical use, the published anxiolytic-vs-medazepam comparison is mechanistically interesting, and the safety profile is favourable. But the evidence framework is Russian rather than Western, with less rigorous trial methodology and limited independent replication. Standard protocol: 200–400 mcg intranasal 2–3× daily, 14-day courses. Pep IQ flags this honestly: the parent compound has a real clinical history in Russia, the anxiolytic mechanism is plausible (GABAergic + BDNF + monoaminergic + immunomodulatory), but Western readers should recognise that 'Russian-approved' is not equivalent to 'FDA-approved' in trial-quality terms. Useful as part of an anxiolytic protocol if you accept that framework.
Selank started as an immunology project at the Institute of Molecular Genetics of the Russian Academy of Sciences. Researchers took tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from the heavy chain of immunoglobulin G that regulates immune function — and extended it with a Pro-Gly-Pro tripeptide at the C-terminus to improve metabolic stability.
Nobody predicted what they got: a compound that not only preserved tuftsin's immunomodulatory properties but crossed into the central nervous system and produced anxiolytic effects comparable to benzodiazepines — without any of the characteristic benzodiazepine side effects. No sedation. No amnesia. No dependence or withdrawal in any animal model tested.
Selank was subsequently approved in Russia and Ukraine for generalised anxiety disorder (GAD) and neurasthenia. The human trial data — while limited and mostly Russian — is some of the most concrete clinical evidence for any peptide in this book's cognitive section. A direct head-to-head comparison against an approved benzodiazepine in 62 anxiety patients is a meaningful data point.
Selank's pharmacology is unusually broad for a heptapeptide. The mechanisms are inter-related rather than independent, and together produce a profile that is distinct from both benzodiazepines and classic nootropics.